Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.12M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.33M

Average 1.23M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$24.59M

FY 2025 · Annual

Investing Cash Flow

$9,000.00

FY 2025 · Annual

Financing Cash Flow

$36.57M

FY 2025 · Annual

+55.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(11.72M)(21.4M)(25.79M)(33.97M)(23.49M)
Depreciation & Amortization93K235K252K266K228K
Deferred Income Tax00000
Stock-Based Compensation5.18M3.57M4.35M3.75M2.09M
Change in Working Capital2.84M(943K)4.85M1.29M(3.46M)
Accounts Receivables(1.11M)(1.41M)2.39M(1.41M)(7.24M)
Inventory00000
Accounts Payables2.17M(1.09M)003.51M
Other Working Capital1.79M1.56M2.46M2.69M270K
Other Non-Cash Items(33K)0318K195K41K
Operating Cash Flow(3.63M)(18.53M)(16.02M)(28.47M)(24.59M)
Capital Expenditures(27K)(171K)(147K)(4K)0
Acquisitions (Net)00009K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(27K)(171K)(147K)(4K)9K
Debt Repayment(268K)(1.4M)(811K)(739K)(353K)
Common Stock Issued44.22M5.32M5.33M24.35M37.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.25M1.62M0(46K)(164K)
Financing Cash Flow53.2M5.55M4.52M23.57M36.57M
Effect of Forex Changes(11K)(1K)4K00
Net Change in Cash49.53M(13.16M)(11.64M)(4.91M)11.99M
Free Cash Flow(3.66M)(18.7M)(16.17M)(28.48M)(24.59M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$23.5M
+ D&A$228.0K
+ Stock-Based Comp$2.1M
+ Deferred Tax$0
- Working Capital-$3.5M
+ Other Non-Cash$41.0K
= Operating Cash Flow-$24.6M
- Capex$0
= Free Cash Flow-$24.6M

Analysis

FY2025 free cash flow is -$24.6M. FCF conversion is 104.7% of net income. Operating cash flow was -$24.6M, with capex of $0. The largest bridge item is Working Capital at -$3.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportOct 22, 2026
10-QQuarterly reportAug 7, 2026
8-KCurrent reportAug 6, 2026

Does CGTX generate free cash flow?

Cognition Therapeutics, Inc. (CGTX) generated -$24.59M of free cash flow in fiscal 2025.

How much operating cash flow does CGTX produce?

Operating cash flow was -$24.59M, before capital expenditures of $0.00.